PD9

(~{E})-2-cyano-~{N},~{N}-diethyl-3-[3-nitro-4,5-bis(oxidanyl)phenyl]prop-2-enamide

Find entries where: PD9

is present as a standalone ligand in 1 entries

Find related ligands:

Chemical Component Summary
Name	(~{E})-2-cyano-~{N},~{N}-diethyl-3-[3-nitro-4,5-bis(oxidanyl)phenyl]prop-2-enamide
Identifiers	(~{E})-2-cyano-~{N},~{N}-diethyl-3-[3-nitro-4,5-bis(oxidanyl)phenyl]prop-2-enamide
Formula	C₁₄ H₁₅ N₃ O₅
Molecular Weight	305.286
Type	NON-POLYMER
Isomeric SMILES	CCN(CC)C(=O)/C(=C/c1cc(c(c(c1)O)O)[N+](=O)[O-])/C#N
InChI	InChI=1S/C14H15N3O5/c1-3-16(4-2)14(20)10(8-15)5-9-6-11(17(21)22)13(19)12(18)7-9/h5-7,18-19H,3-4H2,1-2H3/b10-5+
InChIKey	JRURYQJSLYLRLN-BJMVGYQFSA-N

Chemical Details
Formal Charge	0
Atom Count	37
Chiral Atom Count	0
Bond Count	37
Aromatic Bond Count	6

Drug Info: DrugBank

DrugBank ID	DB00494
Name	Entacapone
Groups	approved investigational
Description	Entacapone is a selective, reversible catechol-O-methyl transferase (COMT) inhibitor for the treatment of Parkinson's disease. It is a member of the class of nitrocatechols. When administered concomittantly with levodopa and a decarboxylase inhibitor (e.g., carbidopa), increased and more sustained plasma levodopa concentrations are reached as compared to the administration of levodopa and a decarboxylase inhibitor.
Synonyms	Entacaponum Entacapona (E)-alpha-Cyano-N,N-diethyl-3,4-dihydroxy-5-nitrocinnamamide N,N-diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl) acrylamide Entacapone
Brand Names	Levodopa, Carbidopa and Entacapone Tablets Entacapone Teva Comtan Carbidopa, levodopa and entacapone Corbilta Mint-entacapone Entacapone Levodopa/carbidopa/entacapone Orion Comtess Entacapone Orion Teva-entacapone Carbidopa, Levodopa and Entacapone Sandoz Entacapone Carbidopa, Levodopa, and Entacapone Stalevo Sandoz Levodopa-carbidopa-entacapone Mylan-entacapone Auro-entacapone Apo-entacapone
Indication	Used as an adjunct to levodopa / carbidopa in the symptomatic treatment of patients with idiopathic Parkinson's Disease who experience the signs and symptoms of end-of-dose "wearing-off".
Categories	Anti-Dyskinesia Agents Anti-Parkinson Drugs Benzene Derivatives Central Nervous System Agents Central Nervous System Depressants COMT Inhibitors Cytochrome P-450 CYP2D6 Inhibitors Cytochrome P-450 CYP2D6 Inhibitors (weak) Cytochrome P-450 Enzyme Inhibitors Dopamine Agents Enzyme Inhibitors Nervous System Phenols UGT1A9 Substrates
ATC-Code	N04BX02
CAS number	130929-57-6

Drug Targets

Name	Target Sequence	Pharmacological Action	Actions
Catechol O-methyltransferase	MPEAPPLLLAAVLLGLVLLVVLLLLLRHWGWGLCLIGWNEFILQPIHNLL...	unknown	inhibitor
Cytochrome P450 2D6	MGLEALVPLAVIVAIFLLLVDLMHRRQRWAARYPPGPLPLPGLGNLLHVD...	unknown	inhibitor
Catechol O-methyltransferase	MPEAPPLLLAAVLLGLVLLVVLLLLLRHWGWGLCLIGWNEFILQPIHNLL...	unknown	inhibitor
UDP-glucuronosyltransferase 1-9	MACTGWTSPLPLCVCLLLTCGFAEAGKLLVVPMDGSHWFTMRSVVEKLIL...	unknown	substrate

Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682